Search
Dec 7, 2024
ASH 2024: The new CEO of Innate Pharma on taking the job and the company's work on antibodies, engagers, and ADCs
Jonathan Dickinson describes what appealed to him about Innate. He discusses the pipeline, including ASH data from the lead program...
Sep 6, 2024
Innate Pharma's Founder & CEO gives an overview of the company's programs and discusses Marseille's strengths in immunology
Hervé Brailly covers lacutamab, monalizumab, the company's NK engager programs, and more.